RE: Opinions.......Greede,
I'm flattered that you'd invite me to comment. Obviously I'm a bit late to the party and much of what I'd say has already been said. I can't speak to the LOR situation as I haven't been following or studying that stock. With respect to FAS, I prefer to stick to stating facts rather than speculation, but one thing I believe is that the value of this stock is going to be determined by the bottom line. As many readers know, many techs and biotechs are priced on what the market believes is the potential value of the companies at some point in the future, thus artificially inflating the market cap. With FAS, I believe that for the near and medium term, the value of the stock is going to be related directly to the balance sheet rather than the prospects for the future. In fact, I believe that the price of the stock is slightly hugher than it should be (gut feel, plus impression I was given when I visited them). There's absolutely nothing wrong with this, and in fact in my mind it's healthier for the company to be valuated this way rather than some pie-in-the-sky potential numbers. Just my humble opinion.
I'm going to be in England again in early October (assuming that the country hasn't run out of petrol by then). I've offered to meet the FAS crew for a post-work pint at the local and they've indicated that they'd be happy to oblige as long as it's before the 10th. Ms. Garcia and Dr. Nicholls are going to be in Toronto from October 10 to 15. If we do manage to connect, I'll be sure to post any interesting tidbits.
Erick